Cargando…

Severe COVID-19 infection in a patient with a blastic transformation of a chronic myeloid leukemia and severe treatment-induced immunosuppression: a case report

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe, leading to the declaration of a pandemic. While most present mild symptoms, it appears as though nearly 20% of confirmed patients develop significant complications. At this time of uncertainty, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mounir, Louardi, Mehdi, Simou, Kawtar, Fahmaoui, Akram, Mansour, Youness, Et-tahir, Meryem, Tabat, Othmane, Joutey Tahiri, Imane, Elkhaouri, Hanane, Ezzouine, Boubakar, Charra, Marieme, Camara, Mouna, Lamchahab, Asmaa, Harrach, Asmaa, Quessar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796834/
https://www.ncbi.nlm.nih.gov/pubmed/33456658
http://dx.doi.org/10.11604/pamj.supp.2020.37.1.25501
Descripción
Sumario:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe, leading to the declaration of a pandemic. While most present mild symptoms, it appears as though nearly 20% of confirmed patients develop significant complications. At this time of uncertainty, we are struggling to provide appropriate care to hematological cancer patients. We need to weigh the risks and benefits of giving cancer treatment against the odds of infecting them with COVID-19. As hematological cancer patients are immunocompromised and there are high chances of exposure during hospital visits, they can get infected and outcome can be fatal. So in this case report, we intend to discuss the possible impact of the current COVID-19 pandemic on patients with acute leukaemia in terms of diagnosis, chemotherapy, and prophylactic measures.